PTC Therapeutics (PTCT) PT Lowered to $25 at Barclays
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts PTCT Hot Sheet
Price: $68.97 +1.25%
Rating Summary:
17 Buy, 6 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Rating Summary:
17 Buy, 6 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Join SI Premium – FREE
Barclays analyst Gena Wang lowered the price target on PTC Therapeutics (NASDAQ: PTCT) to $25.00 (from $26.00) while maintaining a Equalweight rating.
You May Also Be Interested In
- Truist on PTC Therapeutics (PTCT): 'we continue to believe this will be an uphill battle for the company'
- Avis Budget Group (CAR) PT Lowered to $125 at Susquehanna
- ONEOK Inc (OKE) PT Raised to $108 at Argus
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
